These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1007 related articles for article (PubMed ID: 21601352)

  • 1. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
    Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
    van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
    Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.
    Wu GH; Auvinen A; Yen AM; Hakama M; Tammela TL; Stenman UH; Kujala P; Ruutu M; Chen HH
    Eur Urol; 2012 May; 61(5):1011-8. PubMed ID: 22264679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
    Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
    Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.
    van der Cruijsen-Koeter IW; Vis AN; Roobol MJ; Wildhagen MF; de Koning HJ; van der Kwast TH; Schröder FH
    J Urol; 2005 Jul; 174(1):121-5. PubMed ID: 15947595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.
    van Leeuwen PJ; Otto SJ; Kranse R; Roobol MJ; Bul M; Zhu X; de Koning H; Schröder FH
    BJU Int; 2012 Jul; 110(2):188-94. PubMed ID: 22288823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer mortality in the Finnish randomized screening trial.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
    Loeb S; Zhu X; Schroder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies.
    Schröder FH; van den Bergh RC; Wolters T; van Leeuwen PJ; Bangma CH; van der Kwast TH; Roobol MJ
    Eur Urol; 2010 Feb; 57(2):256-66. PubMed ID: 19913350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ; van der Cruijsen IW; Schröder FH
    Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Roemeling S; Roobol MJ; Gosselaar C; Schröder FH
    Prostate; 2006 Jul; 66(10):1076-81. PubMed ID: 16637077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mortality due to prostate cancer in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Results after a 15-year follow-up].
    Luján M; Páez Á; Berenguer A; Rodríguez JA
    Actas Urol Esp; 2012; 36(7):403-9. PubMed ID: 22269382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
    Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam.
    de Vries SH; Postma R; Raaijmakers R; Roemeling S; Otto S; de Koning HJ; Schröder FH
    Eur Urol; 2007 Feb; 51(2):366-74; discussion 374. PubMed ID: 16930812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; van den Bergh RC; Wolters T; Schröder FH
    Eur Urol; 2009 Jan; 55(1):139-46. PubMed ID: 18406045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.